KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $139.9 million.

  • Travere Therapeutics' Operating Expenses rose 1754.01% to $139.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $527.0 million, marking a year-over-year decrease of 602.97%. This contributed to the annual value of $557.0 million for FY2024, which is 442.95% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Operating Expenses is $139.9 million, which was up 1754.01% from $127.1 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Operating Expenses high stood at $180.6 million for Q1 2024, and its period low was $46.4 million during Q4 2021.
  • For the 5-year period, Travere Therapeutics' Operating Expenses averaged around $118.0 million, with its median value being $121.8 million (2024).
  • In the last 5 years, Travere Therapeutics' Operating Expenses tumbled by 7260.42% in 2021 and then skyrocketed by 14984.61% in 2022.
  • Travere Therapeutics' Operating Expenses (Quarter) stood at $46.4 million in 2021, then soared by 149.85% to $116.0 million in 2022, then rose by 20.04% to $139.3 million in 2023, then dropped by 2.71% to $135.5 million in 2024, then grew by 3.25% to $139.9 million in 2025.
  • Its Operating Expenses stands at $139.9 million for Q3 2025, versus $127.1 million for Q2 2025 and $124.4 million for Q1 2025.